Alkem Launches NeuCeno: New Epilepsy Drug in India

1 Minute Read Listen to Article

Sep 16, 2026 22:10

Alkem Laboratories introduces NeuCeno (cenobamate) in India for partial-onset seizures. This new oral therapy offers significant seizure frequency reduction for epilepsy patients.

Alkem Launches NeuCeno: New Epilepsy Drug in India

Key Points

Alkem Laboratories launched NeuCeno, a new epilepsy drug, in India.
NeuCeno (cenobamate) is an oral therapy for treating partial-onset seizures in adults.
Clinical studies showed NeuCeno significantly reduces seizure frequency and can lead to seizure freedom.
This marks the first time cenobamate is available in India, where an estimated 94 lakh people live with epilepsy.

New Delhi, Sep 16 (PTI) Alkem Laboratories on Wednesday announced the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.

The company stated that cenobamate is being launched for the first time in India, where an estimated 94 lakh people live with epilepsy.

NeuCeno is a once-daily oral therapy available in strengths ranging from 12.5 mg to 200 mg tablets.

In clinical studies of adults with uncontrolled focal seizures on existing medications, adjunctive cenobamate showed up to a 78 per cent reduction in seizure frequency, with up to 30 per cent of patients achieving seizure freedom during the maintenance phase, the company said in an exchange filing.

"People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management," said Sandeep Singh, Managing Director of Alkem Laboratories.

Source: PTI By Rediff Money Desk, New Delhi

DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.